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Abstract
Nongovernmental organisations (NGOs) are the main actors of vaccine delivery during complex humanitarian emergencies
such as large population displacements. This paper discusses the use of vaccinations against measles, cholera and meningitis in
this context. The role of NGOs in the advocacy for making new and more eective vaccines available to the most vulnerable
populations is also emphasised. # 1999 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Nongovernmental organisations (NGOs) are often
the main, if not the only, actors of vaccine delivery
during complex humanitarian emergencies. This paper
intends to illustrate how speci®c these interventions are
and to document some of the limits we face with cur-
rently available vaccines.
War, civil strife, persecution, environmental deterio-
ration and/or economic hardship are responsible for
more than 40 million refugees and internally displaced
persons in the world today [1]. From a public health
point of view, these `complex humanitarian emergen-
cies' are always associated with an excess mortality [2].
The major causes of death during the emergency phase
of population displacements are measles, diarrhoeal
diseases, malaria and ARI [3]. These accounted for
50% to 95% of all recorded refugee deaths in
Thailand, Sudan, Malawi and more recently Congo
(ex-ZaõÈre) (Table 1). Sophisticated medical care is of
little use for the prevention and control of these dis-
eases, and the priorities of relief intervention include
the provision of safe water, appropriate shelter and
sanitation, site planning, sucient food ration, immu-
nisation programmes and basic health services [3].
2. Measles vaccination: the number one priority
Measles has been reported as the leading cause of
death in children in several complex emergencies. In
Wad Kowli, Sudan (1985) a severe epidemic resulted
in over 2000 deaths over a 4-month period. In Malawi
(1987±1988), more than 7000 measles cases were
reported over a one-year period among the refugee
population [4]. Because of poor nutritional status, vita-
min A de®ciency and intensive exposure to virus due
to overcrowding, the measles case fatality ratio (CFR)
can be particularly high in refugee settings, sometimes
exceeding 20%. Complications such as secondary pul-
monary infection and malnutrition are frequent [5].
However, the high mortality due to measles is pre-
ventable and mass immunisation coupled with vitamin
A distribution is one of the top priorities at the initial
phase of the intervention [3]. Because of the high
attack rates and measles-speci®c mortality rates among
infants, WHO recommends that, in refugee situations,
all children above 6 months of age be vaccinated
against measles [6]. Children vaccinated between 6 and
9 months must receive a second dose of measles vac-
cine as soon as possible after the age of 9 months in
order to obtain a sucient level of immunity. A mass
immunisation strategy should also target children up
to 12±15 years of age since a shift in age-speci®c inci-
dence from younger to older groups has been
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14 years have been on the rise [5].
Prevention of measles outbreaks in refugee settings
can only be achieved if almost all susceptible individ-
uals have been protected. Given the 85% ecacy of
the measles vaccine when administered at 9 months of
age, it is necessary to aim for a vaccination coverage
level close to 100% in the age group 6 months to 15
years. This objective must be reached during the very
®rst weeks following the population displacement and
maintained over the duration of the crisis through rou-
tine immunisation and vitamin A supplementation of
all newcomers as they arrive [3]. To achieve this, large
logistics operations are often required.
3. New oral cholera vaccines: progress and controversy
Cholera is another major health risk during com-
plex emergencies. Probably the most dramatic epi-
demic aecting refugees happened in Zaire (now
Democratic Republic of Congo) in 1994. On July
that year, some 700,000 people from neighbouring
Rwanda sought refuge in and around the town of
Goma, on the shores of Lake Kivu. The ®rst cases of
cholera were reported a week after the arrival of the
refugees, and the outbreak was responsible for some
eighty thousand 80,000 cases within one month [7].
Forty ®ve thousand deaths were also reported in this
population over the same period, the vast majority
being due to cholera.
Cholera in refugees does not always follow this dra-
matic pattern, and more stable communities are also
aected. Between 1988 and 1993, more than 21 out-
breaks of cholera were reported from 10 Mozambican
refugee camps in Malawi, representing a total of
17,300 cases [8]. Median attack rate was 1.9% and
case fatality ratio was 1.6%. In fact, whatever the epi-
demiological pattern, cholera outbreaks pose serious
problems to relief workers, because they overload, if
not overwhelm, often very fragile relief capacities.
The classical approach of cholera control combining
water and sanitation with outbreak preparedness and
case-management could be improved by the recent
development of eective cholera vaccines administered
orally. The most advanced of these vaccines is the
killed Whole Cell B-Subunit (WC-BS) which has a
®eld-demonstrated eectiveness of 85% for 6 months
in adult [9]. This vaccines requires two doses a week
apart and protection is obtained a week after the sec-
ond dose.
A cost-eectiveness analysis of various cholera con-
trol strategies in refugee settings, including strategies
based on the use of WC-BS vaccine, was carried out
recently [10]. This study concluded that a strategy
combining preemptive treatment (outbreak prepared-
ness and case-management) with preemptive vacci-
nation has the best impact on cholera mortality.
Furthermore, adding preemptive vaccination to pre-
emptive treatment not only saves more lives, but is
also cost-eective when the price of the vaccine falls
below 20 cents per dose.
WC/rBS vaccine is given with a buer and prep-
aration of the solution has to be made on the spot
prior to its administration. In order to assess the feasi-
bility of a mass campaign with this type of vaccine in
a large refugee population, a ®eld study was conducted
in 1997 in Uganda [11]. Some 47,000 Sudanese refu-
gees were immunised with two doses of WC/BS vac-
cine. Total duration of the campaign was 5 weeks.
Vaccine coverage after the second round was 87%,
and drop out proportion between the two rounds was
8%. Vaccine was well accepted by bene®ciaries, except
in very young children who often had diculties to
swallow the rather large quantity of vaccine plus buer
which was oered to them.
These two studies, commissioned by WHO, have
con®rmed that refugee population could bene®t from
new cholera vaccines. However the current price of
these vaccines has been set for the traveler's market
and is not aordable for large scale use in developing
countries. Furthermore, at present, there is no su-
cient stockpile of any oral cholera vaccine readily
available to quickly cover the needs of any large pre-
ventive operation.
Table 1
Major causes of death in selected refugee populations during emergency phases, 1979±1997
Year Host country Causes of death Proportion of reported deaths
1979 Thailand malaria, ARI, diarrhoea 51±92%
1980 Somalia measles, diarrhoea, ARI 60±95%
1985 Sudan measles, diarrhoea 82%
1987 Malawi measles, diarrhoea, malaria 70%
1991 Turkey ARI, diarrhoea 75%
1994 Congo-Zaire (Goma) diarrhoea (cholera and dysentery) 90%
1997 Congo-Zaire (Tingi±Tingi) malaria, ARI, diarrhoea 68%
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Massive epidemics do not always occur in displaced
populations and NGOs also intervene to help develop-
ing countries facing disrupting outbreaks of vaccine
preventable diseases. Meningitis caused by Neisseiria
meningitidis in Sahelian Africa is a good example of
this type of interventions. The control of these epi-
demics is based on reactive mass vaccination triggered
by the crossing of an alert incidence threshold of 15
cases/100,000 population/week averaged over 2 weeks
[12]. In our experience however, interventions based on
this strategy are often launched too late and have only
a limited impact on in the course of the epidemic itself.
The campaign conducted by Me Â decins Sans Frontie Á res
in Togo in 1997 illustrates these limits. This country
has a good surveillance system and alert was given
quickly after the threshold was crossed. Furthermore,
Togo is a small place where population to immunise
could be reached rather easily. The outbreak was re-
sponsible for a total of 2992 cases and 440 deaths (Fig.
1). The vaccination campaign allowed to immunise
60,700 persons and a coverage of 79.1% was achieved.
A study using a mathematical model ®rst described by
Pinner [13] was carried out in order to assess the
impact of the vaccination campaign. In spite of these
favourable context, mass immunisation carried out
after the beginning of the outbreak only prevented
50% of the cases (Fig. 1).
This shows the limits of meningitis control strategies
using the current polysaccaride vaccine, which does
not procure a long lasting immunity and cannot be
given preventively. This also advocate for accelerating
the development of the more immunogenic conjugate
vaccine which should rapidly be made available to
developing countries who would bene®t from it [14].
5. Conclusion
These examples show that NGOs are not only key
players in the delivery of vaccine in emergency situ-
ation, but are also involved in designing and improv-
ing immunisation strategies through operational
research. Meningitis and cholera situations illustrate
the limits of current vaccination strategies. New and
more eective vaccines are being developed who could
greatly improve our capacity to eectively respond to
emergencies, providing that they can be made available
to the poorest countries. In this regards, NGOs such
as Me Â decins Sans Frontie Á res have an increasing role to
play, because they defend the basic human rights of
vulnerable populations. That new vaccines are unavail-
able to such populations because of their price is both
from a humanitarian and a medical ethical perspective
completely unacceptable.
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